应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03839 正大生物
未开盘 11-18 16:08:03
7.700
+0.150
+1.99%
最高
7.700
最低
7.545
成交量
24.15万
今开
7.560
昨收
7.550
日振幅
2.05%
总市值
18.56亿
流通市值
18.54亿
总股本
2.41亿
成交额
182.66万
换手率
0.10%
流通股本
2.41亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
正大生物(03839)发布前三季度业绩 股东应占溢利1214.7万美元 同比减少48.39%
智通财经 · 11-11
正大生物(03839)发布前三季度业绩 股东应占溢利1214.7万美元 同比减少48.39%
正大生物2026年前三季度营收3.32亿美元,净利润0.13亿美元
公告速递 · 11-11
正大生物2026年前三季度营收3.32亿美元,净利润0.13亿美元
正大生物(03839)股东特别大会100%通过2026年HOEL采购总协议
公告速递 · 11-04
正大生物(03839)股东特别大会100%通过2026年HOEL采购总协议
正大生物10月股份变动月报表,股本维持稳定
公告速递 · 11-02
正大生物10月股份变动月报表,股本维持稳定
正大生物(03839)将于11月11日召开董事会审议截至9月30日止九个月未经审计业绩
公告速递 · 10-30
正大生物(03839)将于11月11日召开董事会审议截至9月30日止九个月未经审计业绩
正大生物(03839)拟11月4日召开股东特别大会 审议HOEL采购总协议及年度上限
公告速递 · 10-13
正大生物(03839)拟11月4日召开股东特别大会 审议HOEL采购总协议及年度上限
正大生物公布2026年9月股份变动月报表,股本维持稳定
公告速递 · 10-05
正大生物公布2026年9月股份变动月报表,股本维持稳定
正大生物2026年中期财报:营收2.11亿美元
公告速递 · 09-16
正大生物2026年中期财报:营收2.11亿美元
正大生物更新2026年8月股份变动月报表,股本维持稳定
公告速递 · 09-01
正大生物更新2026年8月股份变动月报表,股本维持稳定
正大生物(03839)公布两项持续关连交易 HOEL采购年销上限最高7.29亿美元
公告速递 · 08-11
正大生物(03839)公布两项持续关连交易 HOEL采购年销上限最高7.29亿美元
正大生物(03839.HK)公布中期业绩 股东应占溢利942.3万美元 同比减少44.72%
智通财经 · 08-11
正大生物(03839.HK)公布中期业绩 股东应占溢利942.3万美元 同比减少44.72%
正大生物(03839)发布中期业绩:上半年股东应占溢利9,423千美元,同比减少44.7%
公告速递 · 08-11
正大生物(03839)发布中期业绩:上半年股东应占溢利9,423千美元,同比减少44.7%
正大生物7月股份变动月报表,股本维持稳定
公告速递 · 08-03
正大生物7月股份变动月报表,股本维持稳定
正大生物(03839)拟于8月11日召开董事会 审议2026年中期业绩及分红事宜
公告速递 · 07-28
正大生物(03839)拟于8月11日召开董事会 审议2026年中期业绩及分红事宜
正大企业国际(03839.HK)拟8月11日举行董事会会议以审批中期业绩
中金财经 · 07-28
正大企业国际(03839.HK)拟8月11日举行董事会会议以审批中期业绩
正大企业国际(03839)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少
智通财经 · 07-22
正大企业国际(03839)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少
正大企业国际(03839.HK)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少
智通财经 · 07-22
正大企业国际(03839.HK)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少
正大企业国际(03839)发布盈利警告:预计2026年上半年股东应占溢利同比降44%至约950万美元
公告速递 · 07-22
正大企业国际(03839)发布盈利警告:预计2026年上半年股东应占溢利同比降44%至约950万美元
正大企业国际预计上半年利润下滑 主因中国养殖业放缓
美股速递 · 07-22
正大企业国际预计上半年利润下滑 主因中国养殖业放缓
正大企业国际预计2026年上半年股东应占溢利950万美元,较2025年同期1700万美元下滑
美股速递 · 07-22
正大企业国际预计2026年上半年股东应占溢利950万美元,较2025年同期1700万美元下滑
加载更多
公司概况
公司名称:
正大生物
所属市场:
SEHK
上市日期:
--
主营业务:
正大企业国际有限公司为一家主要从事生化业务的公司。该公司通过两个分部运营业务。生化业务分部主要从事制造及销售动保化药产品及金霉素。工业业务分部主要从事机械设备贸易及产销汽车零部件。
发行价格:
--
{"stockData":{"symbol":"03839","market":"HK","secType":"STK","nameCN":"正大生物","latestPrice":7.7,"timestamp":1794989283004,"preClose":7.55,"halted":0,"volume":241500,"delay":0,"changeRate":0.019867549668874218,"floatShares":240718310,"shares":241000000,"eps":0.1265,"marketStatus":"未开盘","change":0.15,"latestTime":"11-18 16:08:03","open":7.56,"high":7.7,"low":7.545,"amount":1826602,"amplitude":0.02053,"askPrice":7.7,"askSize":3500,"bidPrice":7.55,"bidSize":500,"shortable":0,"etf":0,"ttmEps":0.671174,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795051800000},"marketStatusCode":0,"adr":0,"listingDate":1435852800000,"exchange":"SEHK","adjPreClose":7.55,"openAndCloseTimeList":[[1794965400000,1794974400000],[1794978000000,1794988800000]],"volumeRatio":2.977364636392364,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03839","defaultTab":"news","newsList":[{"id":"2682130764","title":"正大生物(03839)发布前三季度业绩 股东应占溢利1214.7万美元 同比减少48.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682130764","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682130764?lang=zh_cn&edition=full","pubTime":"2026-11-11 21:48","pubTimestamp":1794404920,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正大生物(03839)发布截至2026年前三季度业绩,该集团取得收入3.32亿美元,同比减少22.98%;归属于股东应占溢利1214.7万美元,同比减少48.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03839","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125896611","title":"正大生物2026年前三季度营收3.32亿美元,净利润0.13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125896611","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125896611?lang=zh_cn&edition=full","pubTime":"2026-11-11 21:47","pubTimestamp":1794404824,"startTime":"0","endTime":"0","summary":"本季度信息\n正大生物于公告中披露,截至2026年9月30日止九个月实现收入3.32亿美元,较上年同期的4.31亿美元下降约23%。同期净利润为0.13亿美元,相比去年同期的0.27亿美元收缩约53%。本期毛利约为0.54亿美元,毛利率约16.2%,较上年同期的13.8%有所提升。\n从成本端来看,报告期内销售及分销成本由去年同期的0.11亿美元增至0.14亿美元,行政及管理费用由0.18亿美元提升至0.21亿美元,反映出运营支出规模有所增加。\n业务分项\n高管解读","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"正大生物2026年前三季度营收3.32亿美元,净利润0.13亿美元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189087646","title":"正大生物(03839)股东特别大会100%通过2026年HOEL采购总协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1189087646","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189087646?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:32","pubTimestamp":1793791929,"startTime":"0","endTime":"0","summary":"正大生物11月4日公告,公司于2026年11月4日召开股东特别大会,就2026年HOEL购买总协定及其项下拟进行的交易及相关年度上限进行表决。议案以投票表决方式获普通决议案通过,赞成票62,897,173票,占表决票数100%;反对票0票,占比0%。\\n\\n公告显示,截至股东特别大会当日,公司已发行股份为240,718,310股。独立股东可投票股份总数为125,170,940股,占已发行股份总数约52.0%。\\n\\n香港中央证券登记有限公司担任本次股东特别大会的点票监票人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188268674","title":"正大生物10月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188268674","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188268674?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:52","pubTimestamp":1793616765,"startTime":"0","endTime":"0","summary":"正大生物控股有限公司于2026年11月2日发布的2026年10月股份变动月报表显示,公司10月期间未发生新增发行或回购注销等活动,整体股本保持稳定。根据公告,截至2026年10月31日,正大生物普通股已发行股份数量为240,718,310股,与上月持平;可换股优先股已发行数量为12,610,777股,同样无任何变化。公告同时披露,正大生物确认已满足香港联交所《上市规则》的最低公众持股量要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158327097","title":"正大生物(03839)将于11月11日召开董事会审议截至9月30日止九个月未经审计业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1158327097","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158327097?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:26","pubTimestamp":1793355988,"startTime":"0","endTime":"0","summary":"正大生物(03839)10月30日公告称,公司董事会已订于2026年11月11日(星期三)举行会议,拟审议并批准公司及其附属公司截至2026年9月30日止九个月的未经审计业绩。\n公告显示,董事会由执行董事谢吉人、李绍庆、谢杰人、马德寿,非执行董事Kobboon Srichai、池添洋一,以及独立非执行董事Surasak Rounroengrom、郑毓和、高明东、章曼琪组成。\n公司表示,将在董事会会议后按规定公布相关业绩及决议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102811499","title":"正大生物(03839)拟11月4日召开股东特别大会 审议HOEL采购总协议及年度上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1102811499","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102811499?lang=zh_cn&edition=full","pubTime":"2026-10-13 19:42","pubTimestamp":1791891731,"startTime":"0","endTime":"0","summary":"正大生物10月14日公告,将于2026年11月4日11:30在香港中环金融街8号国际金融中心二期64楼6411-6416室召开股东特别大会。\\n\\n关键信息:\\n1. 股东名册暂停过户:2026年10月30日至11月4日;登记截止10月29日16:30。\\n\\n会议议程:\\n1. 确认、批准并追认公司与HOEL签订的《2026年HOEL购买总协议》,涉及供应CPBIO产品。\\n2. 审议并批准该协议在截至2027、2028及2029年12月31日止三个财政年度的交易年度上限。\\n\\n符合资格的股东可出席会议或通过代理行使表决权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195531344","title":"正大生物公布2026年9月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1195531344","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195531344?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:15","pubTimestamp":1791188146,"startTime":"0","endTime":"0","summary":"正大生物控股有限公司于2026年10月5日发布截至2026年9月30日的证券变动月报表。公告显示,公司报告期内未发生新增发行、购回及注销股份等变动,股本规模保持稳定。公告同时披露,公司于2025年6月10日通过了购股权计划,目前并未有新的股份期权行使或转让,本月内无新增发行股份。公司截至2026年9月末的法定/注册股本总额约为8,000万美元。公司再次确认其就相关证券类别已满足适用的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148837587","title":"正大生物2026年中期财报:营收2.11亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148837587","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148837587?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:57","pubTimestamp":1789556220,"startTime":"0","endTime":"0","summary":"正大生物公布的2026年中期财报显示,本期公司实现营收约2.11 亿美元,同比下降34.6%,主要因中国养殖业增速放缓及市场竞争加剧所致。毛利率约为16.4%,较去年同期的12.9%有所提升。经营活动所用现金流约为2,376万美元,公司表示将加快国际市场布局,以开拓新增长点。公司主营生物科技板块收入约2.11亿美元,占总营收全部份额,主要来自动保化药产品及金霉素业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"正大生物2026年中期财报:营收2.11亿美元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118493376","title":"正大生物更新2026年8月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1118493376","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118493376?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:13","pubTimestamp":1788250386,"startTime":"0","endTime":"0","summary":"正大生物控股有限公司于2026年9月1日发布2026年8月股份变动月报表,报告期为截至2026年8月31日。根据公告,8月期间公司无新增发行、购回或注销股份,整体股本结构保持稳定。同期,正大生物已披露股份期权计划中,尚无任何股份期权行权或库存股转让的情况。正大生物表示,其将继续严格遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120176823","title":"正大生物(03839)公布两项持续关连交易 HOEL采购年销上限最高7.29亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120176823","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120176823?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:40","pubTimestamp":1786448439,"startTime":"0","endTime":"0","summary":"2026年8月11日,正大生物控股有限公司公告称,公司分别与 High Orient Enterprises Limited及 CPF Private Limited签订新的持续关连交易总协议,涵盖2027年至2029年向HOEL销售动保化药等产品,以及2026年至2028年向CPF(印度)采购原料及相关生物科技产品,并公布未来年度交易上限。公司表示,两项协议有助持续满足HOEL集团对CPBIO产品的需求,并确保正大生物获得具竞争力的原料供应,从而支持业务增长和运营稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997318","title":"正大生物(03839.HK)公布中期业绩 股东应占溢利942.3万美元 同比减少44.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658997318?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:36","pubTimestamp":1786448173,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03839","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168412409","title":"正大生物(03839)发布中期业绩:上半年股东应占溢利9,423千美元,同比减少44.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168412409","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168412409?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:35","pubTimestamp":1786448147,"startTime":"0","endTime":"0","summary":"正大生物控股有限公司8月11日公布,截至2026年6月30日止六个月未经审计的综合业绩。报告期内,集团收入为211,389千美元,同比下降34.6%;毛利34,728千美元,同比减少16.9%。期内,集团整体毛利率由上年同期的12.9%提高至16.4%。除税前溢利为13,455千美元,同比减少44.4%;所得税开支3,306千美元,同比减少21.6%。期内溢利10,149千美元,其中本公司股东应占溢利9,423千美元,同比减少44.7%;每股基本及摊薄溢利皆为3.70美仙。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178262172","title":"正大生物7月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178262172","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178262172?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:07","pubTimestamp":1785755232,"startTime":"0","endTime":"0","summary":"正大生物于2026年8月3日发布2026年7月31日止月度证券变动报告,公司注册名称为正大生物控股有限公司。本次报告期内,各类股份数量及注册股本均未发生变动。公司已发行普通股数量依旧为240,718,310股,且不存在库藏股;已发行可换股优先股数量仍为12,610,777股。公司现有购股权计划未有行权、授予或失效记录,期内未因行使期权产生新股或库藏股变化,目前根据此计划可能发行或转让的股份总数为24,071,831股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103808332","title":"正大生物(03839)拟于8月11日召开董事会 审议2026年中期业绩及分红事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1103808332","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103808332?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:11","pubTimestamp":1785237085,"startTime":"0","endTime":"0","summary":"正大生物7月28日公告,公司董事会将于2026年8月11日(星期二)召开会议,主要议程包括:。公司表示,香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责,并且对其准确性或完整性不作任何声明,也不会就因本公告全部或任何部分内容而引致的任何损失承担责任。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098960","title":"正大企业国际(03839.HK)拟8月11日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098960","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654098960?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:07","pubTimestamp":1785236822,"startTime":"0","endTime":"0","summary":"格隆汇7月28日丨正大企业国际(03839.HK)公告,将于2026年8月11日(星期二)举行董事会会议,藉以(其中包括)批准公司及其附属公司截至2026年6月30日止6个月中期业绩及考虑派发中期股息(如有)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260728/32319863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03839","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754423","title":"正大企业国际(03839)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653754423?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:01","pubTimestamp":1784718082,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正大企业国际(03839)发布公告,本集团预期截至2026年6月30日止6个月(2026年6个月)取得股东应占综合溢利约为950万美元,相比截至2025年6月30日止6个月(2025年6个月)则取得1700万美元。溢利的下降主要是由于集团的金霉素和动保业务业绩受中国养殖行情低迷拖累。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1212","03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653675442","title":"正大企业国际(03839.HK)发盈警,预期中期股东应占综合溢利约为950万美元 同比减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2653675442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653675442?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:01","pubTimestamp":1784718082,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1212","03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195514920","title":"正大企业国际(03839)发布盈利警告:预计2026年上半年股东应占溢利同比降44%至约950万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195514920","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195514920?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718033,"startTime":"0","endTime":"0","summary":"正大企业国际(03839)7月22日公告,根据初步数据显示,公司预期截至2026年6月30日止六个月录得股东应占综合溢利约950万美元,而去年同期(截至2025年6月30日止六个月)则为1,700万美元,同比减少约44.1%。\n公司表示,业绩下滑主要因金霉素及动保业务受中国养殖行情低迷影响所致。\n公告同时指出,公司正在编制2026年上半年未经审核综合业绩,并计划于2026年8月中旬公布正式中期业绩。\n公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123659839","title":"正大企业国际预计上半年利润下滑 主因中国养殖业放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=1123659839","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123659839?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718015,"startTime":"0","endTime":"0","summary":"正大企业国际(CT ENTERPRISE)预期其上半年利润将出现下降,主要归咎于中国动物养殖行业增长放缓带来的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1212","03839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185618534","title":"正大企业国际预计2026年上半年股东应占溢利950万美元,较2025年同期1700万美元下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1185618534","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185618534?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718011,"startTime":"0","endTime":"0","summary":"正大企业国际发布业绩预告,预计2026年上半年归属于公司股东的净利润将达到950万美元,相较于2025年同期的1700万美元,录得显著下降。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1212","03839"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ctei.com.hk","stockEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.102},{"period":"6month","weight":-0.0877},{"period":"1year","weight":0.1324},{"period":"ytd","weight":0.0621}],"compareEarnings":[{"period":"1week","weight":-0.042},{"period":"1month","weight":-0.0369},{"period":"3month","weight":-0.0935},{"period":"6month","weight":-0.0903},{"period":"1year","weight":-0.1016},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"正大企业国际有限公司为一家主要从事生化业务的公司。该公司通过两个分部运营业务。生化业务分部主要从事制造及销售动保化药产品及金霉素。工业业务分部主要从事机械设备贸易及产销汽车零部件。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.545545},{"month":2,"riseRate":0.2,"avgChangeRate":-0.07481},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.012071},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.030248},{"month":5,"riseRate":0.545455,"avgChangeRate":0.014106},{"month":6,"riseRate":0.454545,"avgChangeRate":0.128129},{"month":7,"riseRate":0.545455,"avgChangeRate":0.031502},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.045165},{"month":9,"riseRate":0.333333,"avgChangeRate":0.026481},{"month":10,"riseRate":0.25,"avgChangeRate":0.004227},{"month":11,"riseRate":0.5,"avgChangeRate":0.005958},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.030461}],"exchange":"SEHK","name":"正大生物","nameEN":"CPBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"正大生物(03839)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供正大生物(03839)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"正大生物,03839,正大生物股票,正大生物股票老虎,正大生物股票老虎国际,正大生物行情,正大生物股票行情,正大生物股价,正大生物股市,正大生物股票价格,正大生物股票交易,正大生物股票购买,正大生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"正大生物(03839)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供正大生物(03839)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}